Evidence map›Paper›PMID 33154144›Full record

SynthesisOpen heart2020

Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.

Anna E Ssentongo, Paddy Ssentongo, Emily S Heilbrunn, Alain Lekoubou, Ping Du, Duanping Liao, John S Oh, Vernon M Chinchilli

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Open heart, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 9 pooled it
1.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 9 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Observational
  12. Review
  13. Article
  14. Review
  15. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity.Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Anna E Ssentongo *Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA assentongo@pennstatehealth.psu.edu.ORCID 0000-0001-9104-1323
Paddy Ssentongo *Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Emily S Heilbrunn *Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Alain LekoubouDepartment of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Ping DuDepartment of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Duanping LiaoDepartment of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
John S OhDepartment of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Vernon M ChinchilliDepartment of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Pennsylvania State University · USPenn State Milton S. Hershey Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe association between the use of renin-angiotensin-aldosterone (RAAS) inhibitors and the risk of mortality from COVID-19 is unclear. We aimed to estimate the association of RAAS inhibitors, including ACE inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) with COVID-19 mortality risk in patients with hypertension.

methodsPubMed (MEDLINE) SCOPUS, OVID, Cochrane Library databases and medrxiv.org were searched from 1 January 2020 to 1 September 2020. Studies reporting the association of RAAS inhibitors (ACEi or ARBs) and mortality in patients with hypertension, hospitalised for COVID-19 were extracted. Two reviewers independently extracted appropriate data of interest and assessed the risk of bias. All analyses were performed using random-effects models on log-transformed risk ratio (RR) estimates, and heterogeneity was quantified.

resultsFourteen studies were included in the systematic review (n=73,073 patients with COVID-19; mean age 61 years; 53% male). Overall, the between-study heterogeneity was high (I

conclusionsIn this meta-analysis, with prior use of RAAS inhibitors was associated with lower risk mortality from COVID-19 in patients with hypertension. Our findings suggest a potential protective effect of RAAS-inhibitors in COVID-19 patients with hypertension. PROSPERO REGISTRATION NUMBER: The present study has been registered with PROSPERO (registration ID: CRD 42020187963).

Indexed as

HospitalizationAdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCoronavirus InfectionsCOVID-19FemaleHumansHypertensionMaleMiddle AgedPandemicsPneumonia, ViralAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive Agentsantihypertensive drugshypertensionmeta-analysis

Identifiers

PMID33154144
PMCPMC7646321
OpenAlexW3097409478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.